Chris Boshoff
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Chris Boshoff
May 1, 2024, 12:57 |
Blog
Chris Boshoff: Pfizer in ASCO24
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared a post on LinkedIn:…
May 1, 2024, 10:50 |
Blog
Chris Boshoff: The U.S. FDA granted full approval for our therapy developed with our partner Genmab
Chris Boshoff shared a post on LinkedIn: "Today, the U.S. FDA granted full approval for our…
Feb 9, 2024, 17:30 |
Blog
Chris Boshoff: The U.S. FDA has granted Fast Track designation for our investigational treatment for ER+/HER2- breast cancer
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, posted on LinkedIn: "I’m…
Feb 8, 2024, 17:36 |
Blog
Chris Boshoff: Cancer does not discriminate, and neither should cancer care
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, posted on LinkedIn: "I’m…
Feb 1, 2024, 04:54 |
Blog
Chris Boshoff: The European Medicines Agency (EMA) has accepted our application in collaboration with Astellas Pharma US and Merck for a combination therapy for advanced Urothelial Cancer
Jan 14, 2024, 14:49 |
Blog
Chris Boshoff: The European Medicines Agency approved our Prostate Cancer combination for men living with metastatic castration-resistant prostate cancer
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared on LinkedIn: "I’m proud…
Oct 14, 2023, 17:49 |
Drugs
Chris Boshoff: the U.S. FDA approved our targeted combination therapy for the treatment of adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).
Aug 14, 2023, 16:41 |
Drugs
Chris Boshoff: Science Will Win Against Multiple Myeloma
In a post on LinkedIn by Chris Boshoff, Chief Oncology Research and Development Officer and…
All:
8
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube